乙肝疫苗市场－2026-2031年预测

预计乙肝疫苗市场将从 2025 年的 78.13 亿美元成长到 2031 年的 107.67 亿美元，复合年增长率为 5.49%。

乙肝疫苗市场是全球预防性疫苗产业中至关重要且成熟的细分市场，专注于生产和分销能够预防B型肝炎病毒（HBV）感染的疫苗。乙肝病毒感染是全球重要的公共卫生议题，也是慢性肝病、肝硬化和肝细胞癌的主要原因之一。这种以B肝表面抗原（HBsAg）为基础的疫苗能够高效地预防感染及其严重的长期后果。作为公共卫生策略的基石，市场成长得益于各国完善的免疫规划、全球儿童免疫接种计划的实施以及在高风险成人人群中持续开展的疫苗接种工作。儘管许多婴幼儿市场的疫苗覆盖率较高，但仍存在成长空间，例如透过补种疫苗、成人疫苗宣传活动以及在以往覆盖率较低的地区进行接种工作。

疫苗技术和给药方法

乙肝疫苗是一种重组蛋白疫苗。它是透过将乙肝表面抗原（HBsAg）基因导入酵母细胞而生产的，酵母细胞随后会产生该抗原。接种后，这种纯化的抗原会刺激免疫系统产生保护性抗体，而不会造成实际疾病的风险。此疫苗通常以肌肉注射的方式接种。

标准疫苗接种程序需要接种多剂。婴儿通常接种三剂（出生时、1-2个月和6-18个月），或接种联合疫苗（例如，包含白喉、破伤风、百日咳、脊髓灰质炎和b型流感嗜血桿菌的联合疫苗）。成人可选择标准的三剂接种程序或加速接种程序。一些新型的两剂疫苗核准用于特定年龄组，接种方便，依从性更高。市面上也有单价（单一抗原）疫苗和各种多价合併疫苗。

主要市场驱动因素

最强劲且持续的驱动因素是国家免疫规划（NIP）的实施和加强。世界卫生组织（WHO）建议全民接种B肝疫苗，大多数国家已将其纳入儿童常规免疫接种计画。这为公共卫生采购机构创造了稳定且可预测的需求，从而构成了市场规模的基础。

同时，主导政府和国际卫生组织正在进行公共卫生措施和宣传宣传活动，旨在提高疫苗接种覆盖率，优先考虑医护人员、有多个性伴侣的人和注射毒品的人等高危险成年人群体，并透过针对年龄较大的儿童和青少年的补种疫苗计划来弥补免疫缺口。

全球乙肝相关疾病负担沉重，凸显了疫苗的提案。数百万慢性感染者面临肝癌的风险，疫苗的预防作用促使政策制定者支持疫苗接种并持续投入。此外，开发和采用便利的接种方案，例如两剂疫苗，有助于解决接种依从性问题，并提高青少年和成年人的疫苗接种覆盖率。

市场挑战与趋势

成熟市场面临的主要挑战是，现有的国家免疫规划（NIP）中儿童接种已趋于饱和。这些地区的覆盖率已经很高，限制了疫苗接种量的成长。成长将依赖成人疫苗接种倡议，但这些计划面临许多障碍，例如风险认知不足、接种途径受限以及其他卫生优先事项。

低收入和中等收入国家在疫苗成本和可及性方面的差距也是一大挑战。在诸如全球疫苗免疫联盟（Gavi）等组织的支持下，疫苗可及性已显着改善，但确保永续的资金筹措和健全的低温运输物流仍然是一项持续的挑战。虽然乙肝疫苗的疫苗犹豫程度低于其他疫苗，但在某些社区，疫苗犹豫仍会影响疫苗覆盖率目标的实现。

区域市场动态

北美和欧洲是成熟的高价值市场。成长的动力来自新型疫苗配方（包括联合疫苗和两剂疫苗）的推出、成人疫苗接种的推荐以及资金充足的公共卫生计画。这些地区在创新和下一代候选疫苗的研发方面也处于主导。

亚太地区是全球领先的疫苗市场，拥有巨大的成长潜力，这得益于其庞大的人口规模、历史上较高的疾病负担，以及中国和印度等国透过国家免疫规划（NIP）持续努力实现和维持高疫苗接种覆盖率。此外，该地区还拥有强大的疫苗生产本土基地。

竞争格局与策略重点

该市场呈现寡占格局，由少数几家大型跨国疫苗生产商主导。竞争主要体现在生产规模与成本效益、疫苗形式（单价疫苗与联合疫苗）、安全性以及与国际卫生采购组织的合作强度等。

战略活动涉及多个面向。重点在于结合疫苗的研发与推广。将乙型肝炎病毒（HBV）抗原纳入五价或六价儿童疫苗，可简化免疫接种程序，并带来显着的竞争优势。製造商也正在投资提高产量和供应链可靠性，以满足全球需求。新一代疫苗正在进行临床研发，包括潜在的慢性B型肝炎治疗性疫苗和具有更广泛交叉保护作用的疫苗。此外，与公共卫生组织建立策略伙伴关係，签署长期供应协议，并支持中低收入国家（LMIC）的疫苗宣传活动，对于确立市场地位至关重要。

市场展望

乙肝疫苗市场预计将保持稳定持续成长，这主要得益于其在全球公共卫生领域不可取代的角色。儘管在许多国家，儿童市场已趋于成熟，但未来的扩张仍将受到多种因素的驱动。

未来成长将日益依赖已开发国家和开发中国家成人及青少年疫苗接种覆盖率的提高。简化疫苗接种方案（例如两剂疫苗）的引入和广泛应用将为此提供有力支持。在非洲和亚洲部分地区等历来疫苗覆盖率较低的地区扩大市场，仍将是全球卫生领域的优先事项。治疗性疫苗是一个具有长期潜力的新兴领域，但核心的预防性疫苗市场仍将是主要驱动力。

製造商的成功取决于能否维持最高的品质和安全标准，生产最佳化以实现对高所得市场和全球疫苗免疫联盟（Gavi）支持市场的成本效益供应，以及在其联合疫苗产品组合中进行创新。作为对抗癌症和肝病主要病因的成熟且经济有效的干预措施，乙肝疫苗仍将是全球医疗保健的基石，市场也将不断发展以解决剩余的覆盖缺口和可及性障碍。

本报告的主要优势：

• 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
• 竞争格局：了解全球主要企业的策略倡议，并了解透过正确的策略实现市场渗透的潜力。
• 市场驱动因素与未来趋势：探索推动市场的动态因素和关键趋势，以及它们将如何塑造未来的市场发展。
• 可操作的建议：利用这些见解，在动态环境中製定策略决策，发展新的业务流和收入来源。
• 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

以下是一些公司如何使用这份报告的范例

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

• 2022年至2024年的历史数据和2025年至2031年的预测数据
• 成长机会、挑战、供应链前景、法规结构与趋势分析
• 竞争定位、策略和市场占有率分析
• 按业务板块和地区（包括国家）分類的收入和预测评估
• 公司概况（策略、产品、财务资讯）及主要发展动态。

目录

第一章执行摘要

第二章 市场概览

• 市场概览
• 市场定义
• 调查范围
• 市场区隔

第三章 商业情境

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策与法规
• 策略建议

第四章 技术展望

5. 乙肝疫苗市场（按类型划分）

• 介绍
• 联合疫苗
• 单抗原B型肝炎疫苗

6. 按目标人口分類的B肝疫苗市场

• 介绍
• 婴幼儿
• 儿童
• 成人
• 高危险群

7. 依最终用户分類的B肝疫苗市场

• 介绍
• 医院
• 诊所
• 其他的

8. 各地区乙肝疫苗市场

• 介绍
• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第九章 竞争格局与分析

• 主要企业和策略分析
• 市占率分析
• 合併、收购、协议和合作
• 竞争对手仪錶板

第十章：公司简介

• Novartis AG
• CSL Ltd
• Dyanax Technologies
• Beijing Minhai Biotechnology
• Emergent Biosolutions
• GlaxoSmithKline Biologics
• Merck & Co. Inc.
• Pfizer Inc.
• Sanofi Pasteur
• Serum Institute of India

第十一章附录

• 货币
• 先决条件
• 基准年和预测年时间表
• 相关人员的主要收益
• 调查方法
• 简称

The Hepatitis B vaccine market, with a 5.49% CAGR, is expected to grow to USD 10.767 billion in 2031 from USD 7.813 billion in 2025.

The hepatitis B vaccine market is a critical and mature segment within the global preventative vaccines industry, focused on the production and distribution of immunizations that provide protection against the hepatitis B virus (HBV). HBV infection is a major global health concern, a leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma. The vaccine, which is based on the hepatitis B surface antigen (HBsAg), is highly effective in preventing infection and its severe long-term consequences. As a cornerstone of public health strategy, the market's growth is sustained by established national immunization programs, the inclusion of the vaccine in pediatric schedules worldwide, and ongoing efforts to vaccinate high-risk adult populations. While penetration in many infant markets is high, opportunities for expansion remain in catch-up vaccination campaigns, adult immunization, and in regions with historically lower coverage rates.

Vaccine Technology and Administration

The hepatitis B vaccine is a recombinant protein vaccine. It is produced by inserting the gene for HBsAg into yeast cells, which then produce the antigen. This purified antigen, when administered, stimulates the immune system to produce protective antibodies without any risk of causing the actual disease. The vaccine is typically administered via intramuscular injection.

Standard vaccination schedules involve a multi-dose series. For infants, it is often given as a three-dose series (at birth, 1-2 months, and 6-18 months) or incorporated into combination vaccines (e.g., with diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b). For adults, a standard three-dose schedule or an accelerated schedule is used. A newer two-dose vaccine regimen, approved for use in specific age groups, offers improved convenience and compliance. The market also includes monovalent (single-antigen) vaccines and various multivalent combination products.

Key Market Drivers

The most powerful and sustained driver is the implementation and strengthening of national immunization programs (NIPs). The World Health Organization (WHO) recommends universal hepatitis B vaccination, and most countries have incorporated it into their routine childhood immunization schedules. This creates a stable, predictable demand from public health procurement agencies, forming the volume backbone of the market.

Concurrent with this are ongoing public health initiatives and awareness campaigns led by governments and global health organizations. These efforts aim to increase vaccination coverage, target high-risk adult groups (including healthcare workers, people with multiple sexual partners, and injection drug users), and close immunity gaps through catch-up vaccination programs for older children and adolescents.

The high global burden of HBV-related disease underscores the vaccine's value proposition. With millions chronically infected and at risk for liver cancer, the preventative benefit of vaccination drives continued policy support and investment. Furthermore, the development and adoption of convenient dosing regimens, like the two-dose vaccine, help address compliance challenges and expand uptake in adolescent and adult populations.

Market Challenges and Dynamics

A primary challenge in mature markets is saturation in the pediatric segment within well-established NIPs, where coverage rates are already high, limiting volume growth. Growth in these regions becomes dependent on adult vaccination initiatives, which face barriers like lower perceived risk, access issues, and competing health priorities.

The market also contends with cost and access disparities in low- and middle-income countries (LMICs). While support from organizations like Gavi, the Vaccine Alliance has dramatically improved access, ensuring sustainable financing and robust cold chain logistics remains an ongoing challenge. Vaccine hesitancy, though less pronounced for HBV than for some other vaccines, can still impact coverage targets in certain communities.

Regional Market Dynamics

North America and Europe represent mature, high-value markets. Growth is driven by the adoption of newer vaccine formulations (including combination and two-dose vaccines), adult vaccination recommendations, and stable, well-funded public health programs. These regions also lead in innovation and the development of next-generation vaccine candidates.

The Asia-Pacific region is a dominant market in terms of volume and exhibits significant growth potential. This is due to its large population, high historical disease burden, and continued efforts by countries like China and India to achieve and maintain high coverage rates through their NIPs. The region also has a strong local manufacturing base for vaccines.

Competitive Landscape and Strategic Focus

The market is an oligopoly, dominated by a few large multinational vaccine manufacturers. Competition is based on production scale and cost-efficiency, vaccine presentation (monovalent vs. combination), safety profile, and the strength of partnerships with global health procurement agencies.

Strategic activities are multifaceted. A key focus is on developing and promoting combination vaccines. Incorporating HBV antigen into pentavalent or hexavalent pediatric vaccines simplifies the immunization schedule and is a major competitive advantage. Manufacturers also invest in improving production yields and supply chain reliability to meet global demand consistently. There is ongoing clinical development of next-generation vaccines, including potential therapeutic vaccines for chronic HBV infection and vaccines with broader cross-protection. Furthermore, strategic partnerships with public health entities for long-term supply agreements and support for vaccination campaigns in LMICs are critical for market positioning.

Market Outlook

The hepatitis B vaccine market is positioned for steady, sustainable growth, underpinned by its irreplaceable role in global public health. While the pediatric segment in many countries is mature, future expansion will be driven by several factors.

Growth will increasingly come from enhancing adult and adolescent vaccination coverage in both developed and developing nations. The introduction and wider adoption of simplified regimens (like the two-dose vaccine) will support this. Market expansion in regions with historically lower coverage in Africa and parts of Asia remains a priority for global health. While therapeutic vaccines represent a long-term, high-potential frontier, the core prophylactic market will continue to be the mainstay.

Success for manufacturers will depend on maintaining the highest standards of quality and safety, optimizing production for cost-effective supply to both high-income and Gavi-supported markets, and innovating within the combination vaccine portfolio. As a proven and cost-effective intervention against a major cause of cancer and liver disease, the hepatitis B vaccine will remain a fundamental pillar of preventative healthcare worldwide, with its market evolving to address remaining coverage gaps and convenience barriers.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Key Segment:

• By Type
• Combination Vaccines
• Single Antigen Hepatitis B Vaccines
• By Target Population
• Infants
• Children
• Adults
• High-Risk Population
• By End-User
• Hospitals
• Clinics
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. HEPATITIS B VACCINE MARKET BY TYPE

• 5.1. Introduction
• 5.2. Combination Vaccines
• 5.3. Single Antigen Hepatitis B Vaccines

6. HEPATITIS B VACCINE MARKET BY TARGET POPULATION

• 6.1. Introduction
• 6.2. Infants
• 6.3. Children
• 6.4. Adults
• 6.5. High-Risk Population

7. HEPATITIS B VACCINE MARKET BY END-USER

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Clinics
• 7.4. Others

8. HEPATITIS B VACCINE MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Novartis AG
• 10.2. CSL Ltd
• 10.3. Dyanax Technologies
• 10.4. Beijing Minhai Biotechnology
• 10.5. Emergent Biosolutions
• 10.6. GlaxoSmithKline Biologics
• 10.7. Merck & Co. Inc.
• 10.8. Pfizer Inc.
• 10.9. Sanofi Pasteur
• 10.10. Serum Institute of India

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations